Publicacións nas que colabora con Rodrigo Jover Martínez (72)

2024

  1. Applicability of the Barcelona scale to assess the quality of cleanliness of mucosa at esophagogastroduodenoscopy

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 246-252

  2. Colonoscopy Satisfaction and Safety Questionnaire based on patient experience (CSSQP): A valuable quality tool for all colonoscopies

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 1, pp. 1-13

  3. Use of multi-gene panels in patients at high risk of hereditary digestive cancer: position statement of AEG, SEOM, AEGH and IMPaCT-GENÓMICA consortium

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 3, pp. 293-318

2023

  1. BMPR2 as a Novel Predisposition Gene for Hereditary Colorectal Polyposis

    Gastroenterology, Vol. 165, Núm. 1, pp. 162-172.e5

  2. Fecal occult blood and calprotectin testing to prioritize primary care patients for colonoscopy referral: The advantage study

    United European Gastroenterology Journal, Vol. 11, Núm. 7, pp. 692-699

  3. Rates of repeated colonoscopies to clean the colon from low-risk and high-risk adenomas: Results from the EPoS trials

    Gut, Vol. 72, Núm. 5, pp. 951-957

  4. Role of Artificial Intelligence in Colonoscopy Detection of Advanced Neoplasias : A Randomized Trial

    Annals of internal medicine, Vol. 176, Núm. 9, pp. 1145-1152

  5. Screening uptake of colonoscopy versus fecal immunochemical testing in first-degree relatives of patients with non-syndromic colorectal cancer: A multicenter, open-label, parallel-group, randomized trial (ParCoFit study)

    PLoS Medicine, Vol. 20, Núm. 10

  6. Serum DNA methylome of the colorectal cancer serrated pathway enables non-invasive detection

    Molecular Oncology

  7. Serum methylation of GALNT9, UPF3A, WARS, and LDB2 as noninvasive biomarkers for the early detection of colorectal cancer and advanced adenomas

    Clinical Epigenetics, Vol. 15, Núm. 1

2022

  1. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study

    The Lancet Gastroenterology and Hepatology, Vol. 7, Núm. 2, pp. 118-127

  2. Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs

    Cancers, Vol. 14, Núm. 19

  3. Factors associated with lesion detection in colonoscopy among different indications

    United European Gastroenterology Journal, Vol. 10, Núm. 9, pp. 1008-1019

  4. Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome

    Clinical Gastroenterology and Hepatology, Vol. 20, Núm. 3, pp. 611-621.e9

  5. Risk of Colorectal Cancer and Advanced Polyps One Year after Excision of High-Risk Adenomas

    Diseases of the Colon and Rectum, Vol. 65, Núm. 9, pp. 1112-1120

2020

  1. Clinical and Pathological Characterization of Lynch-Like Syndrome

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 2, pp. 368-374.e1

  2. Increased Th17-Related Cytokine Serum Levels in Patients With Multiple Polyps of Unexplained Origin

    Clinical and translational gastroenterology, Vol. 11, Núm. 3, pp. e00143

  3. Principles for Evaluation of Surveillance After Removal of Colorectal Polyps: Recommendations From the World Endoscopy Organization

    Gastroenterology

  4. Risk of cancer in family members of patients with lynch-like syndrome

    Cancers, Vol. 12, Núm. 8, pp. 1-12

  5. Validation of miR-1228-3p as housekeeping for microRNA analysis in liquid biopsies from colorectal cancer patients

    Biomolecules, Vol. 10, Núm. 1